

# Francesca Romana Ponziani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5231409/publications.pdf>

Version: 2024-02-01

101  
papers

4,139  
citations

109321

35  
h-index

128289

60  
g-index

102  
all docs

102  
docs citations

102  
times ranked

5544  
citing authors

#	ARTICLE	IF	CITATIONS
1	Diet-Induced Alterations in Gut Microbiota Composition and Function. , 2022, , .		1
2	Risk factors for portal vein thrombosis or venous thromboembolism in a large cohort of hospitalized cirrhotic patients. Internal and Emergency Medicine, 2022, 17, 1327-1334.	2.0	6
3	Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs, 2022, 31, 347-360.	4.1	9
4	Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Digestive and Liver Disease, 2022, 54, 452-460.	0.9	38
5	Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma. Hepatology Communications, 2022, 6, 1492-1501.	4.3	22
6	Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. World Journal of Gastroenterology, 2022, 28, 2251-2281.	3.3	23
7	Intestinal Permeability and Dysbiosis in Female Patients with Recurrent Cystitis: A Pilot Study. Journal of Personalized Medicine, 2022, 12, 1005.	2.5	3
8	Missed linkage to care for patients who screened positive for Hepatitis C in a tertiary care centre: Results of the Telepass project. Journal of Viral Hepatitis, 2021, 28, 651-656.	2.0	5
9	Advances in pharmacotherapeutics for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1343-1354.	1.8	5
10	Characterization of the gutâ€‘liverâ€‘muscle axis in cirrhotic patients with sarcopenia. Liver International, 2021, 41, 1320-1334.	3.9	51
11	Correlation Between Liver Function Tests Abnormalities and Interleukin-6 Serum Levels in Patients With SARS-CoV-2 Infection. Gastroenterology, 2021, 160, 1891-1893.	1.3	6
12	Low seroprevalence of SARS-CoV-2 antibodies in cirrhotic patients. Digestive and Liver Disease, 2021, 53, 541-544.	0.9	1
13	Fecal Microbiota Transplantation in Patients with HBV Infection or Other Chronic Liver Diseases: Update on Current Knowledge and Future Perspectives. Journal of Clinical Medicine, 2021, 10, 2605.	2.4	12
14	Italian association for the study of the liver position statement on SARS-CoV2 vaccination. Digestive and Liver Disease, 2021, 53, 677-681.	0.9	13
15	Management of liver disease in Italy after one year of the SARSâ€‘CoVâ€‘2 pandemic: A webâ€‘based survey. Liver International, 2021, 41, 2228-2232.	3.9	13
16	Bariatric Surgery and Liver Disease: General Considerations and Role of the Gutâ€‘Liver Axis. Nutrients, 2021, 13, 2649.	4.1	24
17	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. International Journal of Clinical Practice, 2021, 75, e14755.	1.7	13
18	Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?. Hepatology, 2021, 74, 1718-1718.	7.3	1

#	ARTICLE	IF	CITATIONS
19	Clinical update on the efficacy of anti-SARS-CoV-2 mRNA vaccines in patients on the waiting list for liver transplantation and in liver transplant recipients. <i>Digestive and Liver Disease</i> , 2021, 53, 1232-1234.	0.9	8
20	Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis. <i>Internal and Emergency Medicine</i> , 2021, 16, 1341-1356.	2.0	12
21	Improved gut microbiota features after the resolution of SARS-CoV-2 infection. <i>Gut Pathogens</i> , 2021, 13, 62.	3.4	10
22	COVID-19 as a trigger of irritable bowel syndrome: A review of potential mechanisms. <i>World Journal of Gastroenterology</i> , 2021, 27, 7433-7445.	3.3	37
23	Intestinal Barrier in Human Health and Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12836.	2.6	129
24	Gut Microbial, Inflammatory and Metabolic Signatures in Older People with Physical Frailty and Sarcopenia: Results from the BIOSPHERE Study. <i>Nutrients</i> , 2020, 12, 65.	4.1	98
25	Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges. <i>Nutrients</i> , 2020, 12, 3101.	4.1	17
26	Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 902-903.	3.7	9
27	Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases. <i>Microorganisms</i> , 2020, 8, 1140.	3.6	35
28	Assessing the impact of COVID-19 on the management of patients with liver diseases: A national survey by the Italian association for the study of the Liver. <i>Digestive and Liver Disease</i> , 2020, 52, 937-941.	0.9	53
29	Esophageal microbiome signature in patients with Barrett's esophagus and esophageal adenocarcinoma. <i>PLoS ONE</i> , 2020, 15, e0231789.	2.5	58
30	Effect of liver transplantation on intestinal permeability and correlation with infection episodes. <i>PLoS ONE</i> , 2020, 15, e0235359.	2.5	7
31	Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2 positive patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1060-1068.	3.7	76
32	Contrast-Enhanced Ultrasound in the Short-Term Evaluation of Hepatocellular Carcinoma after Locoregional Treatment. <i>Digestive Diseases</i> , 2020, 38, 522-533.	1.9	7
33	Gut microbiota compositional and functional fingerprint in patients with alcohol use disorder and alcohol-associated liver disease. <i>Liver International</i> , 2020, 40, 878-888.	3.9	68
34	NAFLD or comorbidities, that is the question. <i>Journal of Hepatology</i> , 2020, 73, 723.	3.7	2
35	Letter: liver involvement and mortality in COVID-19 patients – authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1264-1265.	3.7	3
36	Letter: improvement of clinical outcomes by metformin in metabolic liver disease – a microbiota-dependent mechanism?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 474-474.	3.7	0

#	ARTICLE	IF	CITATIONS
37	Going with the gut: probiotics as a novel therapy for hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 295-297.	1.5	2
38	Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice. <i>Cancers</i> , 2019, 11, 1689.	3.7	44
39	Minimal Hepatic Encephalopathy is Associated with Increased Cerebral Vascular Resistance. A Transcranial Doppler Ultrasound Study. <i>Scientific Reports</i> , 2019, 9, 15373.	3.3	7
40	Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591984818.	3.2	47
41	Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible?. <i>European Journal of Radiology</i> , 2019, 114, 32-37.	2.6	8
42	Hepatic encephalopathy 2018: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). <i>Digestive and Liver Disease</i> , 2019, 51, 190-205.	0.9	77
43	Contrast-enhanced ultrasound patterns of hepatocellular adenoma: an Italian multicenter experience. <i>Journal of Ultrasound</i> , 2019, 22, 157-165.	1.3	16
44	Congenital extrahepatic portosystemic shunt: description of four cases and review of the literature. <i>Journal of Ultrasound</i> , 2019, 22, 349-358.	1.3	15
45	Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. <i>Hepatology</i> , 2019, 69, 107-120.	7.3	433
46	Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. <i>World Journal of Gastroenterology</i> , 2019, 25, 4360-4382.	3.3	83
47	Portal vein thrombosis in cirrhosis: Why a well-known complication is still matter of debate. <i>World Journal of Gastroenterology</i> , 2019, 25, 4437-4451.	3.3	47
48	Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation. <i>World Journal of Gastroenterology</i> , 2019, 25, 4814-4834.	3.3	101
49	Low molecular weight heparin as cause of liver injury: case report and literature review. <i>European Review for Medical and Pharmacological Sciences</i> , 2019, 23, 7649-7654.	0.7	6
50	Treatment of early stage chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 519-524.	3.1	6
51	Bile Collection Detected With BrIDA Scintigraphy in a Patient With Hepatocellular Carcinoma. <i>Clinical Nuclear Medicine</i> , 2018, 43, 823-824.	1.3	0
52	Regorafenib: a promising treatment for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1941-1948.	1.8	17
53	Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1301-1311.	3.7	63
54	Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 641-656.	3.0	95

#	ARTICLE	IF	CITATIONS
55	Lack of reduction in serum alpha-fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hepatitis C virus-related cirrhosis. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1493-1500.	2.0	6
56	Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis. <i>Digestive and Liver Disease</i> , 2018, 50, 1105-1114.	0.9	41
57	Sarcopenia in Patients with Advanced Liver Disease. <i>Current Protein and Peptide Science</i> , 2018, 19, 681-691.	1.4	40
58	Portal vein thrombosis occurrence in a cirrhotic patient during treatment with rivaroxaban. <i>Liver International</i> , 2017, 37, 1251-1251.	3.9	6
59	Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports. <i>American Journal of Kidney Diseases</i> , 2017, 70, 297-300.	1.9	14
60	Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2220-2222.	2.3	4
61	Low risk of hepatitis B virus reactivation in patients with resolved infection and chronic myeloid leukemia treated with tyrosine kinase inhibitors. <i>Leukemia and Lymphoma</i> , 2017, 58, 993-995.	1.3	10
62	Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. <i>World Journal of Gastroenterology</i> , 2017, 23, 4491.	3.3	118
63	Thrombosis after liver transplantation for hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0186699.	2.5	8
64	Subclinical atherosclerosis is linked to small intestinal bacterial overgrowth via vitamin K2-dependent mechanisms. <i>World Journal of Gastroenterology</i> , 2017, 23, 1241.	3.3	33
65	Reverse time-dependent effect of alpha-fetoprotein and disease control on survival of patients with Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. <i>World Journal of Hepatology</i> , 2017, 9, 1322-1331.	2.0	2
66	Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C. <i>World Journal of Hepatology</i> , 2017, 9, 352.	2.0	50
67	How to modulate gut microbiota: diet, preprobiotics or antibiotics?. <i>Minerva Gastroenterology</i> , 2017, 63, 411-419.	0.5	1
68	Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 1033-1042.	3.9	28
69	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. <i>Digestive Diseases</i> , 2016, 34, 269-278.	1.9	105
70	Rifaximin for the treatment of irritable bowel syndrome – a drug safety evaluation. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 983-991.	2.4	18
71	Radial Artery as a Coronary Artery Bypass Conduit. <i>Journal of the American College of Cardiology</i> , 2016, 68, 603-610.	2.8	80
72	Reply to Nezcic. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 1021.2-1022.	1.4	0

#	ARTICLE	IF	CITATIONS
73	Diagnosis and treatment of small intestinal bacterial overgrowth. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 215-227.	3.0	40
74	Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. <i>Digestive and Liver Disease</i> , 2015, 47, 689-694.	0.9	17
75	Physiology and pathophysiology of liver lipid metabolism. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1055-1067.	3.0	77
76	Morphological and functional consequences of transradial coronary angiography on the radial artery: implications for its use as a bypass conduit. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 48, 370-374.	1.4	36
77	Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. <i>World Journal of Gastroenterology</i> , 2015, 21, 12322.	3.3	65
78	Portal vein thrombosis and liver transplantation: Implications for waiting list period, surgical approach, early and late follow-up. <i>Transplantation Reviews</i> , 2014, 28, 92-101.	2.9	67
79	Long-term maintenance of sustained virological response in liver transplant recipients treated for recurrent hepatitis C. <i>Digestive and Liver Disease</i> , 2014, 46, 440-445.	0.9	3
80	Liver Transplantation in Alcoholic Patients: Impact of an Alcohol Addiction Unit Within a Liver Transplant Center. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1601-1608.	2.4	156
81	Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound. <i>Journal of Hepatology</i> , 2013, 59, 1014-1021.	3.7	75
82	Treatment of genotype-1 hepatitis C recurrence after liver transplant improves survival in both sustained responders and relapsers. <i>Transplant International</i> , 2013, 26, 281-289.	1.6	7
83	Gut microbiota and metabolic syndrome. <i>Internal and Emergency Medicine</i> , 2013, 8, 11-15.	2.0	66
84	Use and indications of cholestyramine and bile acid sequestrants. <i>Internal and Emergency Medicine</i> , 2013, 8, 205-210.	2.0	75
85	Diagnosis of bowel diseases: The role of imaging and ultrasonography. <i>World Journal of Gastroenterology</i> , 2013, 19, 2144.	3.3	25
86	Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 3255.	3.3	6
87	Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation. <i>World Journal of Gastroenterology</i> , 2013, 19, 7515.	3.3	102
88	Treatment of hepatitis C recurrence is less successful in female than in male liver transplant recipients. <i>Transplant International</i> , 2012, 25, 448-454.	1.6	11
89	What we should know about portal vein thrombosis in cirrhotic patients: A changing perspective. <i>World Journal of Gastroenterology</i> , 2012, 18, 5014.	3.3	46
90	Prevention and treatment of hepatic encephalopathy: Focusing on gut microbiota. <i>World Journal of Gastroenterology</i> , 2012, 18, 6693.	3.3	46

#	ARTICLE	IF	CITATIONS
91	Treatment of recurrent genotype 4 hepatitis C after liver transplantation: early virological response is predictive of sustained virological response. An AISF RECOLT-C group study. <i>Annals of Hepatology</i> , 2012, 11, 338-42.	1.5	5
92	Anticoagulants in Cirrhotic Patients: Controversies and Certainties in PVT Management. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2011, 9, 183-189.	1.0	5
93	Management of Hepatitis C Virus Infection Recurrence After Liver Transplantation: An Overview. <i>Transplantation Proceedings</i> , 2011, 43, 291-295.	0.6	21
94	The metabolic and toxicological considerations for mTOR inhibitors in the treatment of hepatocarcinoma. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 1535-1546.	3.3	7
95	Editorial: Before and after Liver Transplantation. <i>The Open Transplantation Journal</i> , 2011, 5, 30-31.	0.1	0
96	Walking on the Molecular Pathway: m-TOR Inhibition in the Liver Transplant Setting. <i>The Open Transplantation Journal</i> , 2011, 5, 35-43.	0.1	0
97	Bridge Treatments for HCC in the Waiting List for Liver Transplantation. <i>The Open Transplantation Journal</i> , 2011, 5, 44-49.	0.1	0
98	Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment. <i>World Journal of Gastroenterology</i> , 2010, 16, 143.	3.3	248
99	Is there a role for anticoagulants in portal vein thrombosis management in cirrhotic patients?. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1479-1487.	1.8	12
100	Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development. <i>Journal of Hepatology</i> , 2009, 51, 682-689.	3.7	409
101	VIRAL CIRRHOSIS: AN OVERVIEW OF HAEMOSTATIC ALTERATIONS AND CLINICAL CONSEQUENCES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2009, 1, e2009033.	1.3	6